TWI721947B - 抗病毒化合物的固態形式 - Google Patents
抗病毒化合物的固態形式 Download PDFInfo
- Publication number
- TWI721947B TWI721947B TW104117182A TW104117182A TWI721947B TW I721947 B TWI721947 B TW I721947B TW 104117182 A TW104117182 A TW 104117182A TW 104117182 A TW104117182 A TW 104117182A TW I721947 B TWI721947 B TW I721947B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- bis
- phosphate
- imidazol
- salt form
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 475
- 239000007787 solid Substances 0.000 title abstract description 32
- 230000000840 anti-viral effect Effects 0.000 title description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 163
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 126
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 46
- 230000005855 radiation Effects 0.000 claims description 40
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 38
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 27
- 229910019142 PO4 Inorganic materials 0.000 claims description 23
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 23
- 239000010452 phosphate Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 abstract description 20
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- FHCUMDQMBHQXKK-CDIODLITSA-N velpatasvir Chemical compound C1([C@@H](NC(=O)OC)C(=O)N2[C@@H](C[C@@H](C2)COC)C=2NC(=CN=2)C=2C=C3C(C4=CC5=CC=C6NC(=NC6=C5C=C4OC3)[C@H]3N([C@@H](C)CC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)=CC=CC=C1 FHCUMDQMBHQXKK-CDIODLITSA-N 0.000 abstract 1
- 238000002411 thermogravimetry Methods 0.000 description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 49
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 239000002904 solvent Substances 0.000 description 32
- 238000004458 analytical method Methods 0.000 description 30
- 239000013078 crystal Substances 0.000 description 27
- 238000010438 heat treatment Methods 0.000 description 27
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical class OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 27
- 230000004580 weight loss Effects 0.000 description 26
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 23
- 239000012453 solvate Substances 0.000 description 22
- 241000711549 Hepacivirus C Species 0.000 description 20
- 239000004480 active ingredient Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 15
- 238000001757 thermogravimetry curve Methods 0.000 description 14
- 239000002002 slurry Substances 0.000 description 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 12
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 11
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 11
- 229910052805 deuterium Inorganic materials 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 11
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- JZOIFGRYIRQQBI-UHFFFAOYSA-N methyl carbamate;phosphoric acid Chemical compound COC(N)=O.OP(O)(O)=O JZOIFGRYIRQQBI-UHFFFAOYSA-N 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 208000005176 Hepatitis C Diseases 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- UKAWXALBBYVEGN-UHFFFAOYSA-N carbamic acid;dihydrochloride Chemical compound Cl.Cl.NC(O)=O UKAWXALBBYVEGN-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 229940124771 HCV-NS3 protease inhibitor Drugs 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000012296 anti-solvent Substances 0.000 description 2
- HDXZCYGTQRRJME-ZVGUSBNCSA-N carbamic acid (2R,3R)-2,3-dihydroxybutanedioic acid Chemical compound NC(O)=O.O[C@H]([C@@H](O)C(O)=O)C(O)=O HDXZCYGTQRRJME-ZVGUSBNCSA-N 0.000 description 2
- ORSVWFJAARXBHC-UHFFFAOYSA-N carbamic acid;phosphoric acid Chemical compound NC(O)=O.OP(O)(O)=O ORSVWFJAARXBHC-UHFFFAOYSA-N 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000036267 drug metabolism Effects 0.000 description 2
- 230000005496 eutectics Effects 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- JRGDHKNBIJSAIP-UHFFFAOYSA-N methyl carbamate;dihydrochloride Chemical compound Cl.Cl.COC(N)=O JRGDHKNBIJSAIP-UHFFFAOYSA-N 0.000 description 2
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 2
- 238000001907 polarising light microscopy Methods 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- -1 urethane methyl phosphate Chemical compound 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- RSTRKWIPAMGMNJ-LXNKEDDCSA-N CC(C)[C@@H](C(N([C@@H](C)CC1)C1c1nc2ccc(cc(-c(c(CO3)c4)ccc4-c4cnc([C@H](C[C@H](COC)C5)N5C([C@@H](c5ccccc5)NC(OC)=O)=O)[nH]4)c3c3)c3c2[nH]1)=O)NC(O)OC Chemical compound CC(C)[C@@H](C(N([C@@H](C)CC1)C1c1nc2ccc(cc(-c(c(CO3)c4)ccc4-c4cnc([C@H](C[C@H](COC)C5)N5C([C@@H](c5ccccc5)NC(OC)=O)=O)[nH]4)c3c3)c3c2[nH]1)=O)NC(O)OC RSTRKWIPAMGMNJ-LXNKEDDCSA-N 0.000 description 1
- 0 CCCCC1*CC(CCC=C2CC(C)C(C)C*CCC2)C1 Chemical compound CCCCC1*CC(CCC=C2CC(C)C(C)C*CCC2)C1 0.000 description 1
- AVCJRYKKLXSHFD-UHFFFAOYSA-N COC(N)=O.Br.Br Chemical compound COC(N)=O.Br.Br AVCJRYKKLXSHFD-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229940124772 HCV-NS5B polymerase inhibitor Drugs 0.000 description 1
- 239000001358 L(+)-tartaric acid Substances 0.000 description 1
- 235000011002 L(+)-tartaric acid Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 229960001270 d- tartaric acid Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000005445 isotope effect Effects 0.000 description 1
- 238000010983 kinetics study Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000000646 scanning calorimetry Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462010919P | 2014-06-11 | 2014-06-11 | |
| US62/010,919 | 2014-06-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201609745A TW201609745A (zh) | 2016-03-16 |
| TWI721947B true TWI721947B (zh) | 2021-03-21 |
Family
ID=53443009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104117182A TWI721947B (zh) | 2014-06-11 | 2015-05-28 | 抗病毒化合物的固態形式 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9630972B2 (https=) |
| EP (3) | EP3822275A1 (https=) |
| JP (3) | JP2017517532A (https=) |
| KR (3) | KR20190007533A (https=) |
| CN (1) | CN106661042A (https=) |
| AR (1) | AR103194A1 (https=) |
| AU (2) | AU2015274961A1 (https=) |
| BR (1) | BR112016028843A2 (https=) |
| CA (1) | CA2951188C (https=) |
| EA (1) | EA201692220A1 (https=) |
| ES (1) | ES2785409T3 (https=) |
| IL (1) | IL249041A0 (https=) |
| MX (1) | MX2016016299A (https=) |
| PL (1) | PL3154983T3 (https=) |
| PT (1) | PT3154983T (https=) |
| SG (1) | SG11201609810YA (https=) |
| SI (1) | SI3154983T1 (https=) |
| TW (1) | TWI721947B (https=) |
| WO (1) | WO2015191431A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2345657A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| SI2640719T1 (sl) | 2010-11-17 | 2017-07-31 | Gilead Pharmasset Llc | Antivirusne spojine |
| JP6082749B2 (ja) | 2011-11-16 | 2017-02-15 | ギリアド ファーマセット エルエルシー | 抗ウイルス化合物としての縮合イミダゾリルイミダゾール |
| EA201690473A1 (ru) | 2013-08-27 | 2017-03-31 | ГАЙЛИД ФАРМАССЕТ ЭлЭлСи | Комбинированный состав двух противовирусных соединений |
| TW202014413A (zh) | 2014-06-11 | 2020-04-16 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| JOP20170127A1 (ar) | 2016-06-02 | 2017-12-02 | Gilead Pharmasset Llc | صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات |
| CN108368123B (zh) * | 2016-07-08 | 2021-02-19 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的咪唑基化合物及其药物组合物 |
| CN106432253B (zh) * | 2016-09-21 | 2019-06-14 | 上海众强药业有限公司 | 一种维帕他韦新晶型及其制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103328480A (zh) * | 2011-11-16 | 2013-09-25 | 吉利德科学公司 | 作为抗病毒化合物的缩合的咪唑基咪唑 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5858389A (en) | 1996-08-28 | 1999-01-12 | Shaker H. Elsherbini | Squalene is an antiviral compound for treating hepatitis C virus carriers |
| CA2448737C (en) | 2001-07-20 | 2010-06-01 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| JPWO2004089933A1 (ja) * | 2003-04-02 | 2006-07-06 | アステラス製薬株式会社 | フルオロベンズアミド誘導体の新規結晶 |
| KR101164070B1 (ko) | 2003-05-09 | 2012-07-12 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｃ형 간염 바이러스 ｎｓ5ｂ 폴리머라제 억제제 결합 포켓 |
| AR047541A1 (es) | 2004-02-13 | 2006-01-25 | Sandoz Ag | Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas |
| US7157492B2 (en) | 2004-02-26 | 2007-01-02 | Wyeth | Dibenzo chromene derivatives and their use as ERβ selective ligands |
| FR2875409B1 (fr) | 2004-09-17 | 2010-05-07 | Sanofi Aventis | Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose |
| EP1799685B1 (en) * | 2004-09-22 | 2012-03-28 | Pfizer Inc. | Polymorphic forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
| AU2007248282B2 (en) | 2006-05-05 | 2011-12-08 | Merck Patent Gmbh | Crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate |
| US8891379B2 (en) | 2006-06-02 | 2014-11-18 | Riverbed Technology, Inc. | Traffic flow inference based on link loads and gravity measures |
| US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP2009286694A (ja) * | 2006-09-07 | 2009-12-10 | Eisai R & D Management Co Ltd | ５−［２−アミノ−４−（２−フリル）ピリミジン−５−イル］−１−メチルピリジン−２（１ｈ）−オンの塩およびそれらの結晶 |
| CA2823981C (en) | 2006-12-07 | 2016-05-17 | Daiichi Sankyo Company, Limited | Film-coated preparation having improved stability |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5282037B2 (ja) * | 2007-08-10 | 2013-09-04 | 田辺三菱製薬株式会社 | 新規なイソキノリン化合物の塩及びその結晶 |
| ATE551337T1 (de) | 2008-02-12 | 2012-04-15 | Bristol Myers Squibb Co | Inhibitoren des hepatitis-c-virus |
| HRP20120706T1 (hr) | 2008-02-13 | 2012-09-30 | Bristol-Myers Squibb Company | Imidazolil bifenil imidazoli kao inhibitori virusa hepatitisa c |
| US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2732777A1 (en) | 2008-08-07 | 2010-02-11 | Schering Corporation | Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion |
| US20100256184A1 (en) | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US8729077B2 (en) | 2008-11-28 | 2014-05-20 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
| SI2373172T1 (sl) | 2008-12-03 | 2013-12-31 | Presidio Pharmaceuticals, Inc. | Inhibitorji HCV NS5A |
| WO2010065668A1 (en) | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| WO2010096777A1 (en) | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| KR101411889B1 (ko) | 2009-02-27 | 2014-06-27 | 이난타 파마슈티칼스, 인코포레이티드 | Ｃ형 간염 바이러스 억제제 |
| WO2010111673A1 (en) | 2009-03-27 | 2010-09-30 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic hcv inhibitors |
| SG174883A1 (en) | 2009-03-27 | 2011-11-28 | Presidio Pharmaceuticals Inc | Fused ring inhibitors of hepatitis c |
| SG174929A1 (en) | 2009-03-27 | 2011-11-28 | Merck Sharp & Dohme | Inhibitors of hepatitis c virus replication |
| WO2010132538A1 (en) | 2009-05-12 | 2010-11-18 | Schering Corporation | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
| PT3309157T (pt) | 2009-05-13 | 2019-12-02 | Gilead Pharmasset Llc | Compostos antivirais |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EA201290089A1 (ru) | 2009-09-04 | 2012-09-28 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Химические соединения |
| WO2011031904A1 (en) | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
| UA108211C2 (uk) | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| JP2013512246A (ja) | 2009-11-25 | 2013-04-11 | メルク・シャープ・アンド・ドーム・コーポレーション | ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体 |
| US8476225B2 (en) | 2009-12-04 | 2013-07-02 | Gilead Sciences, Inc. | Antiviral compounds |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN104530079B (zh) | 2009-12-18 | 2017-10-20 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
| US20130156731A1 (en) | 2009-12-22 | 2013-06-20 | Kevin X. Chen | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
| EA201290882A1 (ru) | 2010-03-09 | 2013-04-30 | Мерк Шарп Энд Домэ Корп. | Конденсированные трициклические силильные соединения и способы их применения для лечения вирусных заболеваний |
| US9125904B1 (en) | 2010-05-11 | 2015-09-08 | Achillion Pharmaceuticals, Inc. | Biphenyl imidazoles and related compounds useful for treating HCV infections |
| US20110312996A1 (en) | 2010-05-17 | 2011-12-22 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| BR112013004520A2 (pt) | 2010-08-26 | 2016-06-07 | Univ Emory | inibidores potentes e seletivos do virus da hepatite c |
| SG188618A1 (en) | 2010-09-21 | 2013-04-30 | Enanta Pharm Inc | Macrocyclic proline derived hcv serine protease inhibitors |
| WO2012048421A1 (en) | 2010-10-14 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| SI2640719T1 (sl) | 2010-11-17 | 2017-07-31 | Gilead Pharmasset Llc | Antivirusne spojine |
| WO2012087976A2 (en) | 2010-12-21 | 2012-06-28 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| DE112012002748T5 (de) | 2011-10-21 | 2014-07-31 | Abbvie Inc. | Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| HK1201186A1 (en) | 2011-12-29 | 2015-08-28 | Abbvie Inc. | Solid compositions comprising an hcv inhibitor |
| US9079887B2 (en) | 2012-05-16 | 2015-07-14 | Gilead Sciences, Inc. | Antiviral compounds |
| US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| TW201434949A (zh) | 2013-01-31 | 2014-09-16 | Nitto Denko Corp | 環氧組合物及環氧樹脂成形體 |
| EA201690473A1 (ru) | 2013-08-27 | 2017-03-31 | ГАЙЛИД ФАРМАССЕТ ЭлЭлСи | Комбинированный состав двух противовирусных соединений |
| US20150064252A1 (en) | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
| TWI721947B (zh) * | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| TW202014413A (zh) | 2014-06-11 | 2020-04-16 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
| JP2016051146A (ja) | 2014-09-02 | 2016-04-11 | ウシオ電機株式会社 | 光検出装置 |
| EP3588013A1 (de) | 2018-06-26 | 2020-01-01 | XelectriX Power GmbH | Verfahren zur abgabe von elektrischer energie |
-
2015
- 2015-05-28 TW TW104117182A patent/TWI721947B/zh active
- 2015-06-08 EP EP20213940.8A patent/EP3822275A1/en not_active Withdrawn
- 2015-06-08 KR KR1020197001272A patent/KR20190007533A/ko not_active Ceased
- 2015-06-08 EA EA201692220A patent/EA201692220A1/ru unknown
- 2015-06-08 SG SG11201609810YA patent/SG11201609810YA/en unknown
- 2015-06-08 KR KR1020177000696A patent/KR20170015506A/ko not_active Ceased
- 2015-06-08 PT PT157306218T patent/PT3154983T/pt unknown
- 2015-06-08 US US14/733,101 patent/US9630972B2/en active Active
- 2015-06-08 WO PCT/US2015/034649 patent/WO2015191431A1/en not_active Ceased
- 2015-06-08 CN CN201580031460.3A patent/CN106661042A/zh active Pending
- 2015-06-08 KR KR1020207036803A patent/KR20200145852A/ko not_active Ceased
- 2015-06-08 AU AU2015274961A patent/AU2015274961A1/en not_active Abandoned
- 2015-06-08 MX MX2016016299A patent/MX2016016299A/es unknown
- 2015-06-08 PL PL15730621T patent/PL3154983T3/pl unknown
- 2015-06-08 CA CA2951188A patent/CA2951188C/en active Active
- 2015-06-08 EP EP15730621.8A patent/EP3154983B1/en active Active
- 2015-06-08 BR BR112016028843A patent/BR112016028843A2/pt not_active IP Right Cessation
- 2015-06-08 ES ES15730621T patent/ES2785409T3/es active Active
- 2015-06-08 EP EP20155444.1A patent/EP3666775A1/en not_active Withdrawn
- 2015-06-08 SI SI201531097T patent/SI3154983T1/sl unknown
- 2015-06-08 JP JP2016572253A patent/JP2017517532A/ja not_active Withdrawn
- 2015-06-10 AR ARP150101835A patent/AR103194A1/es unknown
-
2016
- 2016-11-17 IL IL249041A patent/IL249041A0/en unknown
-
2017
- 2017-03-15 US US15/459,785 patent/US9884873B2/en active Active
- 2017-12-18 US US15/845,837 patent/US10604530B2/en active Active
-
2018
- 2018-03-19 AU AU2018201948A patent/AU2018201948B2/en active Active
-
2019
- 2019-02-18 JP JP2019026534A patent/JP2019070057A/ja not_active Ceased
- 2019-07-19 JP JP2019133593A patent/JP2019172711A/ja active Pending
-
2020
- 2020-02-21 US US16/797,793 patent/US11203599B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103328480A (zh) * | 2011-11-16 | 2013-09-25 | 吉利德科学公司 | 作为抗病毒化合物的缩合的咪唑基咪唑 |
Non-Patent Citations (1)
| Title |
|---|
| 2013-6-2公開之「關於重結晶的總結---重結晶技術」 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI721947B (zh) | 抗病毒化合物的固態形式 | |
| CN114728899B (zh) | 新型三苯基化合物盐 | |
| JP7710223B2 (ja) | 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用 | |
| CN115403626A (zh) | 新结晶形式 | |
| CN105859709B (zh) | 二氢嘧啶衍生物的复合物及其在药物中的应用 | |
| US20150157614A1 (en) | Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | |
| WO2019237957A1 (zh) | 膦酰胺酯化合物及其盐和相关晶体形式、制备方法和用途 | |
| HK40031882A (en) | Solid forms of an antiviral compound | |
| TWI906614B (zh) | 某些mcl-1抑制劑之鹽及同質多形體 | |
| HK1237346A1 (en) | Solid forms of an antiviral compound | |
| WO2019099761A1 (en) | Solid state forms of elafibranor | |
| HK1236199B (en) | Solid forms of an antiviral compound | |
| HK1236199A1 (en) | Solid forms of an antiviral compound | |
| HK40110051A (zh) | 解旋酶-引发酶抑制剂的固体结晶形式及其制备方法 |